Summary: The Honest Timeline

Robert Cheng signed the consent document. Dr. Sarah Kim went back to her simulation lab. Julia Moreno went back to her office to work on hearing aid coverage. Each of them is operating on a different timeline, and the timelines do not converge. The drug Robert is testing will not benefit from the infrastructure Sarah is building. The policy Julia is advancing will not affect the trial Robert enrolled in. Three pipelines. One question: what arrives when?

What exists now is partially effective and partially deployed. Lecanemab and donanemab are FDA-approved and covered by Medicare with restrictions. They are modestly effective and significantly expensive. They are used by a fraction of patients who could benefit. The state pharmaceutical assistance programs, SHIP counselors, AAA services, and FQHC network from Series 14 exist and are equally underused. The health AI from Series 1, the benefits agent from Series 2, the cognitive baseline from Series 4, the caregiver tools from Series 6, the social connection architecture from Series 7 and 8, the purpose deployment model from Series 11 and 12, the resource infrastructure from Series 14: all available in forms that work. None of them waits for a trial result or a policy change. Each waits for the person who needs it to know it exists.

Over the next two to three years, specific developments are worth watching. Anti-tau Phase III trial results are the most important clinical development for families affected by Alzheimer’s. GLP-1 cognitive protection trial results carry different significance: if semaglutide proves effective, the drug is already approved, already manufactured at scale, and the path from positive results to availability would be measured in months. Multilingual AI validation for clinical applications will determine whether the equity failures of Series 13 begin to close. Household robotics will reach consumers. BEAD broadband deployment progress is trackable by state.

Five to ten years may bring an approved anti-tau therapy. If combined with existing amyloid therapy, the benefit could be meaningfully greater than either alone. If GLP-1 results are positive, a repurposed drug with existing manufacturing infrastructure reaches patients faster and at lower cost than a novel biologic. Household robotics capable of personal care assistance is advancing technically, though the regulatory framework for a robot that touches a person’s body has not kept pace. APOE4 gene therapy is approaching Phase II, with a decade-plus timeline to availability. Quantum-derived drug candidates may enter Phase I trials, the longest timeline in the series.

What requires civic action is specific and named. Medicare dental, vision, and hearing coverage is the most actionable. Federal paid family leave for caregivers is the structural response to a 4.5-year caregiving duration. Broadband as healthcare infrastructure would allow healthcare funding to support the connectivity that healthcare devices require. ADEA enforcement reform would protect the economic security that makes every other recommendation affordable. Each connects directly to a person described earlier in this publication. Each is something a constituent can act on.

Three pipelines. Three timelines. None is fast enough for the person who needs the result today. Each is real, and funded, and advancing. The honest timeline does not promise that the pipelines converge in time for any specific reader. It promises that the work is happening, that the milestones are named, and that the reader who follows them will know the difference between a result and a press release.

Read the full article on BlueMirror.life.